氯替泼诺(Loteprednol Etabonate) - 药物靶点：GR x cPLA2α_在研适应症：干眼综合征，疼痛，眼带状疱疹_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Loteprednol etabonate (JAN/USAN)、Loteprednol Etabonate Ophthalmic Suspension、CDDD-5604

+ [13]

靶点

GR x cPLA2α

作用方式

激动剂

作用机制

GR激动剂(糖皮质激素受体激动剂)、cPLA2α 激动剂(胞内磷脂酶A2 激动剂)

治疗领域

免疫系统疾病感染神经系统疾病+ [3]

在研适应症

干眼综合征疼痛眼带状疱疹+ [10]

非在研适应症

睑缘炎睑缘炎相关角结膜病变白内障+ [8]

原研机构

Bausch & Lomb, Inc.

在研机构

Bausch & Lomb, Inc.Bausch & Lomb (Australia) Pty Ltd.Alcon Laboratories, Inc.

非在研机构

Kala Bio, Inc.Bausch Health Americas, Inc.

W World Corp.

+ [2]

权益机构-

最高研发阶段批准上市

首次获批日期

美国 (1998-03-09),

变应性结膜炎结膜炎睫状体炎+ [7]

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C24H31ClO7

InChIKeyDMKSVUSAATWOCU-HROMYWEYSA-N

CAS号82034-46-6

关联

65

项与氯替泼诺相关的临床试验

NCT05542381

/ RecruitingN/AIIT

The Role of Loteprednol in Reducing Post-Intravitreal Injection Related Pain

Patients are already receiving an intravitreal injection as a standard of care, but they are consenting to receiving a loteprednol drop following the intravitreal injection. This clinical trial is studying the role of loteprednol (corticosteroid) in reducing pain following intravitreal injections for patients with age-related macular degeneration. As of now, there is no definitive pain management technique following intravitreal injections. Loteprednol is a corticosteroid widely used in ophthalmology to treat pain and inflammation, however, it has not been studied as a treatment for pain following intravitreal injections. Our overall goal is to manage pain to improve quality of care after intravitreal injections. Participants will be given either loteprednol, or artificial tears following one visit for an intravitreal injection to test how effective loteprednol is in pain reduction. Pain levels will be assessed by asking participants over the phone about their pain from a scale of 0 to 10 at three different times over a 1-week period. Artificial tear and medication usage will also be tracked over a 1-week period.

开始日期2022-12-22

申办/合作机构

Virginia Polytechnic Institute & State University

[+1]

CTRI/2022/07/044211

/ Not yet recruiting临床3期

A Multicentric Randomized Double Blind Double Dummy Parallel Group Two Arm Comparative Phase III Clinical Study to Evaluate Efficacy Safety and Tolerability of Loteprednol Etabonate Ophthalmic Suspension 1% w/v of Ajanta Pharma Ltd versus Loteprednol Etabonate Ophthalmic Suspension 0.5% w/v in treatment of Post-Operative Inflammatory conditions of Eye - Phase III

开始日期2022-07-25

申办/合作机构

Ajanta Pharma Ltd.

NCT05136443

/ Completed临床4期

Prospective Analysis of Loteprednol Etabonate Ophthalmic Suspension 0.25% for Prevention of Immunologic Rejection After Descemet Membrane Endothelial Keratoplasty

The purpose of this study is to assess off-label use of loteprednol etabonate 0.25% ophthalmic suspension (Eysuvis) for prevention of immunologic rejection in the first year after Descemet membrane endothelial keratoplasty (DMEK). Topical corticosteroids have long been the mainstay for preventing and treating cornea transplant rejection although none are specifically approved for this purpose. The rates of immunologic rejection episodes and steroid-induced ocular hypertension will be compared with the respective rates observed in earlier studies with prednisolone acetate 1% suspension, loteprednol etabonate 0.5% gel, and fluorometholone 0.1% suspension after DMEK.

开始日期2021-11-23

申办/合作机构

Price Vision Group

[+1]

100 项与氯替泼诺相关的临床结果

登录后查看更多信息

100 项与氯替泼诺相关的转化医学

登录后查看更多信息

100 项与氯替泼诺相关的专利（医药）

登录后查看更多信息

355

项与氯替泼诺相关的文献（医药）

2025-08-01·FOOD CHEMISTRY

Investigation into the effects of acute heat stress on stress level, meat quality, myofibrillar proteins properties and serum metabolites release of Muscovy ducks (Cairina moschata)

Article

作者: Huang, Tianran ; Xiao, Mengchao ; Huang, Jichao ; Li, Zimu ; Zhu, Zongshuai ; Huang, Ming

This study systematically investigated the effects of acute heat stress (AHS) on Muscovy ducks, focusing on plasma stress indicators, meat quality, myofibrillar proteins (MPs) properties, and serum metabolite profiles. AHS significantly elevated stress level, impairing meat quality, as evidenced by higher L* value, shear force, drip loss, and cooking loss (P < 0.05). It also induced MPs oxidation and aggregation, reflected by elevated carbonyl content, turbidity, zeta potential, and particle size. MPs structural alterations were confirmed by fluorescence quenching and increased exposure of hydrophobic groups. Correlation analysis revealed strong associations between physicochemical changes and MPs oxidation. Metabolomic analysis identified 161 and 105 differential metabolites in the CON vs. LS and CON vs. SS comparisons, respectively, involving 25 metabolic pathways related to energy, amino acids, and fatty acids. These findings provide novel insights into the molecular pathways of AHS-induced meat quality deterioration and reveal potential intervention timing for the poultry industry.

2025-06-01·EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Overcoming barriers in formulating practically insoluble loteprednol etabonate in ophthalmic nanoemulsion

Article

作者: Petriček, Igor ; Bočkor, Luka ; Juretić, Marina ; Krtalić, Iva ; Špoljarić, Drago ; Kocbek, Petra ; Pepić, Ivan ; Lovrić, Jasmina ; Kučuk, Maša Sufundžić ; Hafner, Anita ; Dukovski, Bisera Jurišić ; Ljubica, Josip

Loteprednol etabonate (LE) is a soft corticosteroid recently approved for the short-term treatment of signs and symptoms of dry eye disease. LE is available on the market as a suspension, which can release only limited amount of dissolved corticosteroid after application at the ocular surface. This study is focused on the development of an oil-in-water nanoemulsion (NE) to effectively deliver dissolved LE to the ocular surface, in order to promote its absorption. We newly developed an extended-throughput 3D model of the corneal epithelium for biocompatibility study, and an innovative approach to investigate the effect of biorelevant dilution on LE release from the NE oil phase. Castor oil, Capryol® 90, Kolliphor® EL and Soluplus® were selected as NE excipients based on their potential to dissolve LE. Design of experiments was successfully employed to develop biocompatible and physically stable NE with high LE content (0.15 %, w/w) and retention efficiency (87 % after 10 months of storage at room temperature). LE retention within oil droplets (above 90 % of the initial LE content) despite biorelevant dilution simulating tear turnover suggests the potential for direct LE absorption from the NE oil droplets into the lipophilic corneal epithelium. The results obtained encourage the extension of the studies in terms of in vitro permeability and in vivo eye-related bioavailability assessment to prove the potential of the proposed LE formulation.

2025-05-01·INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

Loteprednol etabonate alleviates NLRP3 inflammasome-associated inflammatory diseases in mice by suppressing the transcription of IL-1β

Article

作者: Li, Weiling ; Huang, Weichen ; Fu, Zhengqi ; Xie, Shoufeng ; Yao, Yulin ; Wan, Pin ; Ye, Lirui ; Peng, Qian ; Liu, Yuchen ; He, Qi ; Sun, Binlian

Excessive activation of the NLRP3 inflammasome leads to cellular inflammation and tissue damage. Finding an inhibitor of its activation is urgent need for NLRP3 inflammasome-associated inflammatory diseases. In this study, we identified Loteprednol etabonate (LE), a well-known anti-inflammatory drug for ocular conditions, as a potent inhibitor of NLRP3 inflammasome activation through screening an FDA-approved drug library. In cellular models, LE significantly reduced IL-1β transcription, suppressed NLRP3 inflammasome activation, and finally inhibited the maturation and secretion of IL-1β and GSDMD-mediated pyroptosis. Mechanistic investigations showed that LE might inhibit IL-1β transcription by blocking both NF-κB and AP-1 signaling pathways. Furthermore, in mouse models of NLRP3 inflammasome-associated inflammatory diseases, including LPS-induced sepsis and DSS-induced colitis, intraperitoneal injection of LE significantly suppressed inflammatory response and improved mice survival rate. Collectively, these findings identify LE as a novel inhibitor of NLRP3 inflammasome activation, offering a promising therapeutic strategy for the treatment of NLRP3 inflammasome-associated inflammatory diseases.

62

项与氯替泼诺相关的新闻（医药）

2025-05-29

·FiercePharma

Alcon gains first FDA prescription drug nod since Novartis split, scoring with drops for dry eye disease

Alcon has gained its first FDA nod for a prescription product since its 2019 split with Novartis, securing an approval for dry eye disease treatment Tryptyr. Six years after being spun out from Novartis and becoming a public company, eye care specialist Alcon has gained its first FDA approval for a prescription drug, scoring a nod for dry eye disease (DED) treatment Tryptyr (acoltremon ophthalmic solution).Tryptyr, which is administered as a single drop twice daily, is a first-in-class TRPM8 receptor agonist intended to activate tear production. “Tryptyr is the first eye drop that stimulates corneal nerves to directly address tear deficiency, a known cause of (DED),” Marjan Farid, M.D., professor of ophthalmology at the University of California, Irvine, said in a release.There are roughly 38 million in the U.S. who have DED. Fewer than 10% of those who have been diagnosed are being treated with a prescription product, according to Alcon.“We believe Tryptyr is an exciting new treatment option for a significant number of dry eye patients given its rapid efficacy,” David Endicott, CEO of Alcon, said in a release, adding that the approval was a “tremendous milestone” for the 80-year-old company. The company said it expects to launch Tryptyr in the third quarter.Backing the nod were two phase 3 trials that included more than 930 DED patients. In one study, 43% of patients on Tryptyr had a 10-millimeter increase in natural tear production on the Schirmer test at Day 14, compared to 8% of those on vehicle. In another study, the figures came in at 53% versus 14%, favoring the Tryptyr arm.After operating as a Novartis subsidiary for eight years, Alcon split from the Swiss pharma giant in 2019. Since then, Alcon has been on a growth splurge. In 2022, it paid $770 million to acquire Aerie Pharmaceuticals and its marketed glaucoma and ocular hypertension meds Rhopressa and Rocklatan. The company also ponied up $355 million to gain U.S. rights to Novartis’ Simbrinza, which treats the same ocular conditions. Also in 2022, Alcon gained DED treatment Eysuvis as part of a $60 million transaction with struggling Kala Pharmaceuticals.In addition, two months ago, Alcon secured a majority stake in clinical-stage company Aurion Biotech.In February, Alcon reported 2024 revenue at $9.8 billion, which was up 5% from the prior year.

临床结果并购临床3期上市批准

2025-05-29

·Firstwordpharma

Alcon's dry eye treatment Tryptyr secures FDA nod

The FDA approved Alcon's Tryptyr (acoltremon) eye drops for managing dry eye disease (DED), marking the first prescription product approved for the eye care company since its spin-out from Novartis as an independent publicly traded company.“We believe Tryptyr is an exciting new treatment option for a significant number of dry eye patients given its rapid efficacy," said Alcon CEO David Endicott. Tryptyr, earlier codenamed AR-15512, entered Alcon’s portfolio in 2022 through its acquisition of Aerie Pharmaceuticals for nearly $770 million.With this approval — the first-in-class TRPM8 receptor agonist that stimulates corneal sensory nerves to rapidly increase natural tear production — gains a lead in DED therapeutics over Aldeyra’s investigational RASP modulator reproxalap rejected twice by the FDA, initially in 2023 and once again last month.Tryptyr’s approval is supported by robust clinical data from the Phase III COMET-2 and COMET-3 trials. Results showed that participants receiving Tryptyr experienced at least a 10 mm increase in natural tear production at day 14 compared with control vehicle — 42.6% versus 8.2% in COMET-2 and 53.2% versus 14.4% in COMET-3. Notably, Tryptyr demonstrated significant tear production as early as day 1, with consistent results maintained through day 90. Alcon noted that Tryptyr will be available as a 0.003% ophthalmic solution in single-dose vials for twice-daily administration. The company anticipates a US launch in the third quarter, with international market expansion plans on the cards. Earlier this month, Stifel analysts seemed optimistic about the drug’s approval but flagged concerns that may temper its launch, including transient burning or stinging side effects and mixed symptomatic results that could limit labelling, alongside growing competition in the DED space.Besides Tryptyr, other FDA-approved DED therapies include Alcon's Eysuvis (loteprednol etabonate) — bought from Kala Pharmaceuticals in 2022 and Bausch + Lomb's Xiidra (lifitegrast) — gained from Novartis a year later. Alcon also markets a range of over-the-counter dry-eye products such as Systane Dry Eye Drops and GenTeal Tears.

临床结果临床3期上市批准并购

2025-05-19

·药通社

国内滴眼液，只围着一个剂型卷？

国办发53号文提到要促进仿制药质量提升，将仿制药质量和疗效一致性评价逐步向滴眼剂、贴剂、喷雾剂等剂型拓展。贴剂和喷雾剂近期发展良好，品种国内外的技术壁垒早已突破，多款被原研垄断多年的品种接连仿制上市，旨在与原研一较高下。但国内的滴眼液仿制一直陷在困局里。简单易研发的溶液型，过评多，竞争过大；技术壁垒高的混悬型和乳剂型，研发困难上市少，无力参与竞争。围着一个剂型卷？目前国内滴眼液市场很卷，而且基本围着一个剂型卷。目前国内已上市的滴眼液约90%均为溶液型，仿制领域更甚，按照参与一致性评价审批企业数量由高到低排序，排前的全部都是溶液型滴眼液。与之对比，混悬型和乳剂型极为罕见，仅有零星几个上市品种。溶液型之所以多，是因为门槛低、工艺成熟、审批路径清晰。许多企业一头扎进来，结果是整个市场猛地成了红海。我们来看一下卷的最多的前三个品种。玻璃酸钠滴眼液，国内市场体量最大的滴眼液品种之一，2023年全平台销售接近20亿元。目前已有59家企业获批，45家企业已过评，26家企业在上市申请流程。然而这么多家企业竞争、已经进入集采的品种，市场却依然被两个未中标的原研把控。2021年2月，第四批集采该品种就被纳入，原研未中标，到了2023年，URSAPHARM（海露）和参天制药（爱丽）两款原研相加仍占据7成市场，完全不受集采影响。中标的四家企业市场尚且如此难堪，更何况剩下没中标的40多家企业？地夸磷索钠滴眼液，2017年，参天制药（丽爱思）在国内获批上市，市场增长速度惊人，2020年市场不过一千多万，到了2021年就增涨到了八千多万，也正是在2021年，国内仿制企业嗅到了该品种的潜力，大量企业开始进行仿制。截至目前，地夸磷索钠滴眼液已有过评企业42家，尚有21家企业在走上市申请流程，2023年11月，该品种被纳入第九批集采，五家企业中标，品种还没真正发展起来，就面临了集采降价，2024年二季度，在各省份集采价格陆续落实之后，销售额直接缩减四分之三。现今，地夸磷索钠滴眼液全平台销售额不到2亿元，怎么撑得起如此多家企业的竞争？盐酸莫西沙星滴眼液，由诺华研发，于2018年12月在中国获批进口，2019年被纳入国家医保目录乙类，2021年6月被纳入第五批集采。此品种更是卷的让人出乎意料，全平台市场不过两千多万，却已有41家企业过评，并有9家企业在走上市申请流程。滴眼液不是一个市场特别大的品类，全平台销售额TOP1品种就是玻璃酸钠滴眼液，竞争少也许有利可图，可惜溶液型滴眼液普遍情况是市场有限，竞争激烈。卷不过换个方向？如上文所说，混悬型和乳剂型滴眼液目前现状是，研发难，上市少。目前混悬型和乳剂滴眼剂的相关情况如下：上市品种就那么几个，参比公布了挺多，但仿制成功的就一款兴齐眼药的环孢素滴眼液(Ⅱ) 。单从仿制成功的环孢素滴眼液(Ⅱ)来看，兴齐眼药2020年过评上市，市场发展良好，23年就到了3.5亿市场，独家品种至今没有竞争对手。市场增长速率和整体情况均表现良好，自然吸引其他企业想要分一杯羹，只是有意入局的企业不得不承认，混悬型和乳剂型滴眼剂工艺复杂，仿制难度较高。目前环孢素滴眼液在研企业不多，进度最快的是广东众生的环孢素滴眼液（III）已进入发补阶段，广州大光则提交了上市申请。其他混悬、乳剂型滴眼液进度更是寥寥。氯替泼诺妥布霉素滴眼液，山东辰欣佛都药业股份有限公司于2025年1月9日提交了上市申请。氯替泼诺混悬滴眼液，津药和平（天津）制药有限公司于2022年12月20日提交了上市申请。妥布霉素地塞米松滴眼液，中山万汉制药有限公司于2024年2月8日提交了上市申请。其余品种，暂无提交上市申请企业。仿制难，新研发更难，混悬型和乳剂型滴眼剂能参与竞争的没几家。难在哪里？又如何突破？混悬型和乳剂型滴眼剂均属于复杂滴眼剂，目前国内外均无专门针对复杂滴眼剂的指导原则。难度一：工艺复杂滴眼剂一般要求Q1、Q2与参比制剂保持一致，复杂滴眼剂的处方可能需要加助悬剂、乳化剂等辅料，且不同的辅料型号对产品质量有很大影响，所以需特别关注所用辅料的型号问题。生产工艺较复杂，可能需要分步灭菌，即原辅包分别灭菌后再无菌灌装，无菌/灭菌工艺的影响因素较多，十分考验企业的GMP管理水平及无菌保障能力。对于混悬型滴眼液，需关注原料药粒度（为避免刺激性，原料药粒度一般不大于10μm），可能会涉及到无菌研磨。难度二：质量研究要求高抑菌效力：多剂量滴眼剂一般应加适当抑菌剂。经前期文献调研发现，对于抑菌效力的要求，中国严于美国和日本。部分来自日本的参比制剂，其抑菌效力可能无法满足中国药典A或B的要求，那么仿制药可能就需要调整抑菌剂的种类或用量，以满足中国药典抑菌效力要求，切实保障眼用制剂安全性，降低眼部微生物的感染风险。单剂量滴眼剂装量：我国目前单剂量批准了从0.2-1.0ml不等的装量，结合实际临床使用，比较推荐的单剂量滴眼剂的装量是0.4mL。滴出量：滴眼剂的滴出量不仅受滴眼剂本身特性，如密度、粘度等因素的影响，同时还受滴眼剂用塑料瓶的影响。FDA规定滴出量范围为20-70μl，仿制药与参比制剂在±10%范围内。粒度分布：混悬型滴眼剂质量研究通常应包含粒度和粒度分布的研究。需关注样品的制备方法，同时粒度测定方法需经过验证以确保方法的准确性和可靠性，可考虑采用群体生物等效性（PBE）研究等分析方法进行数据对比，以确保仿制药质量与参比制剂的一致性。体外释放：需关注体外释放方法的筛选，应具有一定的区分力，能够反映处方工艺参数的变化。FDA为支持复杂眼用制剂的仿制，专门资助针对复杂眼用制剂的相关研究，其中就包括开发更接近体内生理条件的新型体外释放方法。样品批次要求：由于复杂滴眼剂处方工艺及质量控制的复杂性，其质量对比研究的样品批次一般要求不低于3批。滴眼液虽然不是市场极大的品类，但若是能研发出一两个强势品种，也未必不能出现黑马，比如兴齐眼药，凭借自研的两款滴眼液，环孢素滴眼液和硫酸阿托品滴眼液大杀四方。与其卷在同一个类目同一个品种，不如去突破一下，或许会有机会成为下一个兴齐眼药。参考：药事纵横↓ 扫码加入药通社交流群 ↓投稿/企业合作/内容沟通：华籍美人（Ww_150525）

一致性评价上市批准医药出海

100 项与氯替泼诺相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01689	氯替泼诺	S01BA14	DB14596

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
干眼综合征	美国	Alcon Laboratories, Inc.	2020-10-26
疼痛	美国	Bausch & Lomb, Inc.	2011-04-15
眼带状疱疹	中国	Bausch & Lomb, Inc.	2007-01-10
结膜炎	美国	Bausch & Lomb, Inc.	1998-03-09
变应性结膜炎	美国	Bausch & Lomb, Inc.	1998-03-09
睫状体炎	美国	Bausch & Lomb, Inc.	1998-03-09
虹膜炎	美国	Bausch & Lomb, Inc.	1998-03-09
角膜炎	美国	Bausch & Lomb, Inc.	1998-03-09
疱疹性角膜炎	美国	Bausch & Lomb, Inc.	1998-03-09
眼部炎症	美国	W World Corp.	1998-03-09
术后炎症	美国	Bausch & Lomb, Inc.	1998-03-09
玫瑰痤疮	美国	Bausch & Lomb, Inc.	1998-03-09
季节性过敏性结膜炎	美国	Bausch & Lomb, Inc.	1998-03-09

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
干燥综合征性角膜结膜炎	临床3期	美国	Kala Bio, Inc.	2016-06-01
术后疼痛	临床3期	美国	Kala Bio, Inc.	2016-06-01
眼部感染	临床3期	美国	Kala Bio, Inc.	2014-05-01
白内障	临床3期	美国	Bausch & Lomb, Inc.	2013-06-01
睑缘炎	临床3期	新加坡	Bausch & Lomb, Inc.	2009-10-01
睑缘炎相关角结膜病变	临床3期	新加坡	Bausch & Lomb, Inc.	2009-10-01
睑板腺功能障碍	临床2期	美国	Kala Bio, Inc.	2014-07-01
术后并发症	临床1期	加拿大	Sandoz International GmbH	2018-04-26
眼睛疼痛	临床1期	美国	Bausch Health Americas, Inc.	2015-02-01
糖尿病性黄斑水肿	临床阶段不明	美国	Kala Bio, Inc.	2014-07-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05136443 (CTgov)	临床4期	器官移植排斥 \| 角膜水肿 \| 虹膜角膜内皮综合征	70	loteprednol etabonate 0.25% ophthalmic suspension	獵鑰鬱鑰遞齋製鬱製餘 = 築獵憲構網鏇範築糧鹹夢鹹鬱淵鑰繭獵膚衊選 (鑰淵膚遞餘蓋鬱鹽範遞, 願廠餘餘糧衊構齋鹹鑰 ~ 壓鑰鬱衊鹹憲選選獵齋) 更多	-	2024-08-14
NCT05136443 (Pubmed \| Cornea) 人工标引	临床4期	Fuchs内皮营养不良	70	Loteprednol Etabonate 0.25% ophthalmic suspension	鏇蓋餘醖壓構範壓夢簾(觸襯願膚鬱願鬱範廠願) = 膚艱願艱顧鬱鏇醖獵衊衊襯鬱鏇壓範簾選願糧 (醖鏇餘觸製衊願範齋淵 ) 更多	积极	2024-08-01
NCT04555694 (CTgov)	临床4期	干眼综合征	30	Cyclosporine+loteprednol etabonate (Restasis and Lotemax)	糧顧醖襯淵積網遞醖糧(壓遞範廠壓繭築構獵衊) = 願構衊艱網窪襯積製觸廠顧顧觸餘範範繭構觸 (衊窪蓋觸廠壓鑰艱鑰鬱, 1.5) 更多	-	2023-10-11
				Cyclosporine+Dexamethasone Ophthalmic 0.4 Mg Ophthalmic Insert (Restasis and Dextenza)	糧顧醖襯淵積網遞醖糧(壓遞範廠壓繭築構獵衊) = 蓋鹽構遞鬱蓋遞膚構繭廠顧顧觸餘範範繭構觸 (衊窪蓋觸廠壓鑰艱鑰鬱, 1.0) 更多
NCT02120079 (CTgov)	临床4期	干眼综合征	37	In Vivo Confocal Microscopy (IVCM)+Lotemax (Lotemax)	遞膚壓顧繭觸蓋夢餘夢(壓鹽廠構遞獵蓋築艱觸) = 顧範鬱衊艱淵築觸廠遞膚觸簾鏇廠遞鏇簾鑰窪 (鬱壓廠築構積夢鏇構願, 5.13) 更多	-	2022-03-23
				In Vivo Confocal Microscopy (IVCM)+Soothe Tired Eyes Lubricant Eye Drop (Artificial Tears) (Soothe Tired Eyes Lubricant Eye Drop (Artificial Tears))	遞膚壓顧繭觸蓋夢餘夢(壓鹽廠構遞獵蓋築艱觸) = 網選觸願鑰醖壓積網構膚觸簾鏇廠遞鏇簾鑰窪 (鬱壓廠築構積夢鏇構願, 26.09) 更多
AAO2021	N/A	钱币状湿疹	100	Tacrolimus 0.1%	壓鏇願鬱選壓繭網遞築(範壓膚構夢構齋鹹構鏇) = 齋製鹹觸構夢築積簾糧憲選餘選壓鬱鹹鹽醖遞 (網糧顧窪獵鏇廠廠築繭 )	-	2021-11-13
				Loteprednol 0.5%	壓鏇願鬱選壓繭網遞築(範壓膚構夢構齋鹹構鏇) = 製鏇窪觸構繭蓋顧選觸憲選餘選壓鬱鹹鹽醖遞 (網糧顧窪獵鏇廠廠築繭 )
ARVO2021	N/A	-	-	Loteprednol Etabonate Eluting Adhesive Ocular Patch	築廠範鬱壓網構餘鏇鹽(膚構夢膚夢廠願簾獵鬱) = 窪艱願襯鏇夢廠憲蓋淵顧糧構觸艱衊網夢積獵 (鑰齋網醖襯積夢繭願選 ) 更多	-	2021-06-01
ARVO2021	N/A	-	-	Loteprednol etabonate (submicron) ophthalmic gel 0.38%	願壓衊製範積廠簾蓋廠(鑰夢遞壓構膚繭衊夢範) = 鹹蓋鹽襯築糧鑰餘餘鬱淵鹽蓋繭衊網構選蓋製 (蓋積遞選獵範壓鹹築簾, 1.3)	-	2021-06-01
				Prednisolone acetate ophthalmic suspension 1.0%	願壓衊製範積廠簾蓋廠(鑰夢遞壓構膚繭衊夢範) = 鏇簾鏇襯壓襯觸餘餘艱淵鹽蓋繭衊網構選蓋製 (蓋積遞選獵範壓鹹築簾, 1.39)
NCT03616899 (STRIDE 3, CTgov)	临床3期	干燥综合征性角膜结膜炎	901	KPI-121 Ophthalmic Suspension (KPI-121 0.25% Ophthalmic Suspension)	獵積繭顧積壓製願憲築(鏇憲憲網糧醖齋襯願艱) = 簾願鏇鬱鬱淵憲鹹襯築壓顧衊鹹壓範製鹹範糧 (鹹築積衊網淵鏇醖艱網, 19.379) 更多	-	2021-04-02
				Vehicle (Vehicle of KPI-121 0.25% Ophthalmic Suspension)	獵積繭顧積壓製願憲築(鏇憲憲網糧醖齋襯願艱) = 糧鏇構衊鏇觸鏇遞窪淵壓顧衊鹹壓範製鹹範糧 (鹹築積衊網淵鏇醖艱網, 17.579) 更多
NCT02218489 (Maui, CTgov)	临床2期	睑缘炎 \| 睑板腺功能障碍	206	Vehicle (Vehicle)	淵衊壓鹽淵鏇廠壓鑰窪(齋鏇艱廠鬱襯鹹壓範鹽) = 蓋鹽蓋顧膚蓋鹹顧網醖衊蓋網獵餘繭餘鏇範夢 (繭憲膚餘艱繭獵憲夢構, 13.8) 更多	-	2021-01-11
				KPI-121 (KPI-121 0.25% Ophthalmic Suspension)	淵衊壓鹽淵鏇廠壓鑰窪(齋鏇艱廠鬱襯鹹壓範鹽) = 蓋積蓋糧繭艱憲襯壓艱衊蓋網獵餘繭餘鏇範夢 (繭憲膚餘艱繭獵憲夢構, 16.7) 更多
NCT02188160 (Kauai, CTgov)	临床2期	干燥综合征性角膜结膜炎	150	KPI-121 (KPI-121 0.25% Ophthalmic Suspension)	範鹹鑰醖壓網範餘構糧(鬱淵製膚願壓憲構齋遞) = 鏇網蓋網衊廠蓋窪淵鹽襯積艱願蓋鹽網鑰範廠 (襯願夢鹹夢遞餘繭積鏇, 0.633) 更多	-	2021-01-06
				Placebo (Vehicle)	範鹹鑰醖壓網範餘構糧(鬱淵製膚願壓憲構齋遞) = 築鑰淵夢餘積餘網淵獵襯積艱願蓋鹽網鑰範廠 (襯願夢鹹夢遞餘繭積鏇, 0.626) 更多